Why the study?
Does standardized 123I-MIBG imaging accurately estimate short- and long-term mortality risk in patients with chronic heart failure?
Does standardized 123I-MIBG imaging accurately estimate short- and long-term mortality risk in patients with chronic heart failure?
Standardization of 123I-MIBG imaging protocols allows for universal application of heart-to-mediastinum ratios to estimate mortality risk in chronic heart failure.
May facilitate CHF risk stratification; leaves open prospective validation of derived models.
123I-meta-iodobenzylguanidine (MIBG) is a potent prognostic marker of chronic heart failure (CHF). However, inter-institutional variations due to methodological variations required minimization before 123I-MIBG findings could be universally applied to the diagnosis, treatment and prognosis of CHF. Therefore, protocols including data acquisition, setting regions of interest for calculating heart-to-mediastinum ratios (HMR) and cross-calibration of HMR among institutions required standardization. A cross-calibration phantom was introduced to overcome institutional differences, and a large amount of experimental data were collected, which enabled multicenter comparisons and the creation of large-scale prognostic databases. Thereafter, cardiac mortality risk models to estimate short- and long-term (two and five years, respectively) mortality were created based on a standardized 123I-MIBG HMR. The ability of these models to accurately determine prognosis is currently undergoing validation.
No takes yet. Share an insight, caveat, or question.
Kenichi Nakajima (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: